Skip to content
2000
Volume 20, Issue 3
  • ISSN: 1574-8863
  • E-ISSN: 2212-3911

Abstract

Introduction

It is essential to exclude other causes, such as autoimmune diseases and bacterial infections, before attributing cutaneous/systemic vasculitis to drug use.

Case Study

This report discusses the case of a young man who developed multi-organ failure and cutaneous vasculitis following the use of antifungal medications (terbinafine and itraconazole) for dermatophyte infections. Tests for autoimmune diseases and infections were negative. Given his drug history and a skin biopsy indicating leukocytoclastic vasculitis, it was inferred that the vasculitis was likely drug-induced. Despite treatment with steroids, intravenous immunoglobulins, and plasmapheresis, the patient did not survive, possibly due to delayed diagnosis and treatment.

Conclusion

In community practice, Drug-induced Vasculitis (DIV) is frequently overlooked. When patients present with skin rash, fever, and multi-organ dysfunction, DIV should be considered, particularly in the context of recent drug use. Over-the-counter antifungals, like terbinafine or itraconazole, can cause DIV and may be fatal if not promptly diagnosed and treated.

Loading

Article metrics loading...

/content/journals/cds/10.2174/0115748863327130240909044620
2024-09-19
2025-09-01
Loading full text...

Full text loading...

References

  1. Ortiz-SanjuánF. BlancoR. HernándezJ.L. Drug-associated cutaneous vasculitis: Study of 239 patients from a single referral center.J. Rheumatol.201441112201220710.3899/jrheum.140390 25225278
    [Google Scholar]
  2. MerkelP.A. Drug-induced vasculitis.Rheum. Dis. Clin. North Am.200127484986210.1016/S0889‑857X(05)70239‑8 11723768
    [Google Scholar]
  3. RadićM. Martinović KaliternaD. RadićJ. Drug-induced vasculitis: A clinical and pathological review.Neth. J. Med.20127011217 22271809
    [Google Scholar]
  4. FlendrieM. VissersW.H.P.M. CreemersM.C.W. de JongE.M.G.J. van de KerkhofP.C.M. van RielP.L.C.M. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: A prospective study.Arthritis Res.200573R666R67610.1186/ar1724 15899052
    [Google Scholar]
  5. DoyleM.K. CuellarM.L. Drug-induced vasculitis.Expert Opin. Drug Saf.20032440140910.1517/14740338.2.4.401 12904096
    [Google Scholar]
  6. GeislerJ.P. SchraithD.F. ManahanK.J. SoroskyJ.I. Gemcitabine associated vasculitis leading to necrotizing enterocolitis and death in women undergoing primary treatment for epithelial ovarian/peritoneal cancer.Gynecol. Oncol.200492270570710.1016/j.ygyno.2003.10.050 14766271
    [Google Scholar]
  7. SchmorlP. Heer-SonderhoffA. VosshenrichR. ConradS. Cerebral vasculitis associated with gemcitabine.Urologe A201049226827010.1007/s00120‑009‑2203‑1 20213928
    [Google Scholar]
  8. MahtoS.K. SheoranA. VermaP. WarG. AgarwalN. SinghA. Leukocytoclastic vasculitis: An uncommon adverse effect of a common drug.J. Family Med. Prim. Care2019862137213910.4103/jfmpc.jfmpc_338_19 31334194
    [Google Scholar]
  9. JagatiA. ChaudharyR.G. RathodS.P. ZankatD. BrarA. MahadeviaB. Oral antifungal therapy: Emerging culprits of cutaneous adverse drug reactions.Indian Dermatol. Online J.201910212513010.4103/idoj.IDOJ_353_18 30984585
    [Google Scholar]
  10. HassaanZ.R.A.A. MohamedH.A.K. EldahshanR.M. ElsaieM.L. Comparison between the efficacy of terbinafine and itraconazole orally vs. the combination of the two drugs in treating recalcitrant dermatophytosis.Sci. Rep.20231311903710.1038/s41598‑023‑46361‑z 37923859
    [Google Scholar]
  11. World Health Organization (WHO)-Uppsala Monitoring Centre. The use of the WHO-UMC system for standardized case causality assessment.Available from: http://www.who-umc.org/Graphics/24734.pdf
  12. U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1.Available from: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf
  13. YadavC.K. RankaR. PandaP.K. ShahB.P. MishraM.K. KrishnanV. Amoxicillin Induced Fever, Rash, and Catatonia - A Case Study.Curr. Drug Saf.202419228228510.2174/1574886318666230308094209 36892033
    [Google Scholar]
  14. DohertyM.J. Algorithms for assessing the probability of an Adverse Drug Reaction.Respir. Med. CME200922636710.1016/j.rmedc.2009.01.004
    [Google Scholar]
  15. ParthasarathiG. RameshM. Nyfort-HansenK. NagaviB.G. Clinical pharmacy in a South Indian teaching hospital.Ann. Pharmacother.200236592793210.1345/aph.1A223 11978174
    [Google Scholar]
  16. HadiM.A. NeohC.F. ZinR.M. ElrggalM. CheemaE. Pharmacovigilance: Pharmacists’ perspective on spontaneous adverse drug reaction reporting.Integr. Pharm. Res. Pract.20176919810.2147/IPRP.S105881 29354555
    [Google Scholar]
  17. WiikA. Drug-induced vasculitis.Curr. Opin. Rheumatol.2008201353910.1097/BOR.0b013e3282f1331f 18281855
    [Google Scholar]
  18. Abdul-KarimR. RyanC. RangelC. EmmettM. Levamisole-Induced Vasculitis.Proc. Bayl. Univ. Med. Cent.201326216316510.1080/08998280.2013.11928946 23543977
    [Google Scholar]
/content/journals/cds/10.2174/0115748863327130240909044620
Loading
/content/journals/cds/10.2174/0115748863327130240909044620
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test